Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934912 | 1.00 | JUN (0.66) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL4121496 | 0.92 | JUN (0.78) | JUNNFKB1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4128281 | 0.92 | JUN (0.78) | JUNNFKB1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL11716698 | 0.88 | JUN (0.55) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL17173781 | 0.88 | JUN (0.55) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL11716701 | 0.88 | JUN (0.55) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL2219674 | 0.87 | NFKB1 (0.85) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL20144408 | 0.87 | JUN (0.69) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL2294213 | 0.85 | JUN (0.68) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 | |
| SCHEMBL2294216 | 0.85 | JUN (0.68) | JUNNFKB1ALOX5KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105153055-B | Propenyl benzene is acylated the triazole derivatives of 1,5 diaryl 1,2,4, its preparation method and medical usage | 中国药科大学 | 2017-10-24 | — | — | CN | disclosed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3130340-A1 | ISOACTEOSIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9475752-B2 | Method for manufacturing 3,4,5-tricaffeoylquinic acid | FUJIFILM CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475752-B2 | Method for manufacturing 3,4,5-tricaffeoylquinic acid | FUJIFILM CORPORATION (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | FUJIFILM CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | FUJIFILM CORPORATION (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20150291645-A1 | ISOACTEOSIDE DERIVATIVE AND USE THEREOF | SINPHAR PHARMACEUTICAL CO., LTD. (TW) | 2015-10-15 | — | — | US | disclosed |
| US-5047555-A | Antiallergens, Antiinflammatory Agents | TANABE SEIYAKU CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0374048-A1 | 4-Aminophenol derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-20 | — | — | EP | disclosed |
| EP-0140327-B1 | BIS-DIOXOPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTITUMOR AGENTS COMPRISING THEM AND COMPOSITIONS CONTAINING THEM | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0174064-B1 | COMPOSITIONS AND COMPOUNDS FOR THE TREATMENT OF PROSTATIC ADENOMA | INVERNI DELLA BEFFA S.P.A. (IT) | 1989-12-06 | — | — | EP | disclosed |
| EP-0265185-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| US-4709076-A | UROGENITAL DISORDERS | INVERNI DELLA BEFFA SPA (IT) | 1987-11-24 | — | — | US | disclosed |
| EP-0227431-A1 | Heterocyclic amides | BEECHAM GROUP PLC (GB) | 1987-07-01 | — | — | EP | disclosed |
| US-4650799-A | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0174064-A2 | Compositions and compounds for the treatment of prostatic adenoma | INVERNI DELLA BEFFA S.P.A. (IT) | 1986-03-12 | — | — | EP | disclosed |
| EP-0140327-A2 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023986-A1 | METHOD FOR MANUFACTURING 3,4,5-TRICAFFEOYLQUINIC ACID | HAAO, CUL5, ACMSD | JUN 3619/4885NFKB1 593/4885ALOX5 147/4885 |
| US-20150291645-A1 | ISOACTEOSIDE DERIVATIVE AND USE THEREOF | CPT1A, UGT8, HSD11B2 | JUN 1508/4885NFKB1 2223/4885ALOX5 653/4885 |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | SLCO1B1, SLCO2B1, SLCO1B3 | JUN 2163/4885NFKB1 835/4885ALOX5 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.